Alle Storys
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
Intercell AG and Biological E. Ltd Enter into a Strategic Alliance for the Development, Manufacture and Sales of its Japanese Encephalitis Vaccine

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Vienna (Austria), March 17, 2005 - Intercell AG, a leading developer
of next generation vaccines for the prevention and treatment of major
infectious diseases, announced today that it has signed an agreement
with Biological E. Ltd. (Hyderabad, India), for the development,
manufacture and sales of its Japanese Encephalitis vaccine in Asia. 
This is an important step in the implementation of Intercell’s global
marketing and commercialization strategy for its modern cell culture
based Japanese Encephalitis vaccine. Intercell is planning to market
the product independently from the alliance with Biological E in the
United States, Europe and Australia targeting the travelers and armed
forces market to replace current suboptimal vaccines produced on
mouse brain. In order to optimally cover and meet the requirements of
the market where the disease is endemic, Intercell has been seeking
for a strategic alliance for the marketing and selling of its vaccine
in certain Asian countries.
Biological E. will be Intercell's strategic partner for marketing and
selling the Japanese Encephalitis vaccine in certain Asian countries.
Under the terms of the agreement, Biological E. will manufacture the
product in India for the Asian endemic market.
Intercell AG and Biological E anticipate that they will broaden their
strategic alliance by collaborating on the development of future
vaccines by combining the strength of Intercell’s Antigen
Identification Program in identifying new, protective antigens with
Biological E’s experience as a leading Asian vaccine manufacturer.
"A safe and effective high-standard Japanese Encephalitis vaccine for
adults and in particular children in the endemic areas throughout
Asia will meet a high medical need", states Gerd Zettlmeissl, Chief
Operating Officer of Intercell AG.
"This agreement with a leading Asian vaccine manufacturer leverages
the commercialization of our Japanese Encephalitis vaccine and will
be another step in our efforts to continue to develop and
commercialize our broad portfolio of vaccine candidates and
Dr. Vijay Kumar Datla, Chairman and Managing Director of Biological
E. Limited added: "We are excited about this partnership with
Intercell that enables us to offer a novel and safe vaccine to combat
Japanese Encephalitis. There is an urgent need to respond to this
epidemic throughout India and Asia where large-scale immunization is
critical. Our partnership furthers the aim of ensuring a sustainable
supply at the earliest."
About Intercell’s JE vaccine 
Intercell´s novel Japanese Encephalitis vaccine is a purified,
inactivated vaccine for active immunization of adults against the
Japanese Encephalitis virus and has successfully concluded Phase II
clinical trials and will start Phase III clinical trials in 2005.
In a Phase II head-to-head comparison with JE-VAX®, Intercell’s
vaccine was shown to be:
• Less reactogenic - both in frequency and intensity
• More potent - higher antibody levels at all doses studied one month
after the immunizations; this vaccine also showed high seroconversion
rates one month after a single dose
• More convenient - 2 doses versus 3 doses and liquid versus
freeze-dried format
• More persistent - higher persistence of antibodies two years after
primary immunization
About Biological E. Ltd
Over the last 50 years, Biological E. Ltd. (BE) has been a leading
vaccine and pharmaceutical company. The company produces a range of
critical vaccines and has been an active partner in the National
Immunization Program of India. The company is currently commissioning
large scale cGMP facilities in order increase its capacities and
product range to offer these vaccines on a global basis. In addition
to its current pipeline of combination vaccines that are entering
pivotal trials, BE has R&D programs to develop novel vaccines for
both vector borne and enteric diseases. The company has entered into
a number of strategic collaborations with leading biotech companies
and research institutes for basic R&D. Biological E. is a privately
held company.
For more information please visit:
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
The information contained herein is not for publication or
distribution in the United States of America. This press release is
not an offer of securities for sale in the United States. Securities
may not be offered or sold in the United States absent registration
or an exemption from registration under the U.S. Securities Act of
1933, as amended. Any public offering of securities to be made in the
United States will be made by means of a prospectus that may be
obtained from Intercell AG and that will contain detailed information
about the company and management, as well as financial statements.
end of announcement                    euro adhoc 17.03.2005 08:56:29 

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303

Branche: Biotechnology
ISIN: AT0000612601
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG